```html

Quasi‑Inflammatory Bowel Disease (Quasi‑IBD)

Overview

Quasi‑inflammatory bowel disease (Quasi‑IBD) is a term used to describe a group of chronic gastrointestinal disorders that share many clinical and endoscopic features with classic inflammatory bowel disease (IBD – Crohn’s disease and ulcerative colitis) but lack the full‑thickness intestinal inflammation or the histologic hallmarks of true IBD. The condition is sometimes referred to as “IBD‑like colitis,” “microscopic colitis‑type IBD,” or “immune‑mediated enteropathy.”

• Who it affects: Most patients are adults aged 30–60, with a slight female predominance (≈55%). However, pediatric cases have been reported, especially in adolescents with a family history of auto‑immune disease.
• Prevalence: Because Quasi‑IBD is not captured in most national registries, exact numbers are uncertain. Large‑scale colonoscopy series estimate a prevalence of 0.1‑0.3 % of the general population, roughly 1‑3 cases per 1,000 adults. Among patients evaluated for chronic diarrhea, up to 8 % may meet criteria for a Quasi‑IBD phenotype (Mayo Clinic, 2022).
• Why the name? “Quasi” (Latin for “as if”) reflects that the disease mimics IBD in presentation and response to therapy but does not meet the strict pathological definition.

Symptoms

Symptoms can be intermittent or persistent and often overlap with other functional GI disorders. The most common presentations include:

• Diarrhea: Usually watery, 3‑10 BMs per day, may be nocturnal.
• Abdominal pain/cramping: Typically left‑lower‑quadrant, worsens after meals.
• Urgency and fecal incontinence: A sudden need to defecate that can lead to accidents.
• Weight loss: Usually modest (<10 % of body weight) but can be more marked in severe disease.
• Fatigue: Related to chronic inflammation and possible micronutrient deficiencies.
• Bloody stools: Less common than in classic IBD (≈5 % of cases) but may occur if superficial ulcerations develop.
• Tenesmus: A sensation of incomplete evacuation.
• Extra‑intestinal manifestations: Joint pain, skin rashes (e.g., erythema nodosum), and eye irritation (uveitis) occur in 10‑15 % of patients, mirroring classic IBD patterns.
• Growth retardation (children): Delayed height/weight gain due to chronic malabsorption.

Causes and Risk Factors

The exact etiology of Quasi‑IBD remains under investigation, but current evidence points to a multifactorial process:

Immune dysregulation

Abnormal activation of the gut‑associated lymphoid tissue leads to a low‑grade, mucosa‑restricted inflammatory response. Cytokine profiles (elevated IL‑6, TNF‑α) resemble those seen in ulcerative colitis, but the infiltrate is confined to the lamina propria without deep ulceration.

Genetic predisposition

Genome‑wide association studies (GWAS) have identified shared risk loci with IBD, especially variants in IL23R, HLA‑DRB1, and ATG16L1. Family aggregation studies show a 2‑fold increased risk among first‑degree relatives.

Microbiome alterations

Patients often exhibit reduced diversity, with decreased *Faecalibacterium prausnitzii* and increased *Escherichia coli* spp., suggesting dysbiosis as a trigger.

Environmental triggers

• Medications: Long‑term non‑steroidal anti‑inflammatory drugs (NSAIDs), proton‑pump inhibitors (PPIs), and selective serotonin reuptake inhibitors (SSRIs) have been implicated.
• Smoking: Increases risk, especially in women.
• Dietary factors: High‑fat, low‑fiber Western diets correlate with symptom flares.
• Infections: Post‑infectious onset after bacterial gastroenteritis (e.g., *Campylobacter*, *Salmonella*) has been reported.

Who is most at risk?

Risk factor	Relative risk (approx.)
Family history of IBD or autoimmune disease	2–3×
Current smoker	1.8×
Long‑term NSAID use (>6 months)	1.5×
Age 30–60	Highest incidence
Female sex	≈1.2×

Diagnosis

Diagnosing Quasi‑IBD requires a systematic approach to exclude infectious, neoplastic, and classic IBD causes while confirming the characteristic mucosal pattern.

Initial evaluation

• Comprehensive history (symptom chronology, medication use, family history).
• Physical examination focusing on abdominal tenderness, perianal disease, and extra‑intestinal signs.

Laboratory tests

• Complete blood count (CBC) – may show mild anemia.
• C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – modest elevation.
• Stool studies – culture, ova & parasites, Clostridioides difficile PCR to rule out infection.
• Fecal calprotectin – often elevated (30‑200 µg/g), supporting an inflammatory process.
• Serologic panels – anti‑Saccharomyces cerevisiae antibodies (ASCA) and p‑ANCA are less specific but may aid differentiation.

Imaging & endoscopy

• Colonoscopy with biopsies: The gold standard. Findings include:
  • Normal-appearing mucosa or mild erythema.
  • Microscopic inflammation limited to the lamina propria.
  • Absence of deep ulcerations, granulomas, or transmural thickening.
• Capsule endoscopy: Useful for small‑bowel assessment when colonoscopy is inconclusive.
• Cross‑sectional imaging (CT or MR enterography): Typically normal or shows only mild wall thickening, helping to rule out Crohn’s disease.

Diagnostic criteria (proposed)

1. Chronic (≥4 weeks) diarrhea or abdominal pain.
2. Endoscopic evidence of mucosal inflammation without deep ulceration.
3. Histology showing lamina‑propria infiltrates of lymphocytes/plasma cells with spared crypt architecture.
4. Exclusion of infectious, neoplastic, and classic IBD causes.

Treatment Options

Management aims to control symptoms, reduce inflammation, and prevent complications. Treatment is individualized based on disease severity, comorbidities, and patient preferences.

Medications

• Aminosalicylates (5‑ASA): Mesalamine (2.4–4.8 g/day) is first‑line for mild–moderate disease; works locally in the colon.
• Bud​esonide: A locally acting corticosteroid (9 mg/day) effective for short‑term flares with fewer systemic side effects.
• Systemic corticosteroids: Prednisone 40‑60 mg/day for severe exacerbations, tapered over 6‑8 weeks.
• Immunomodulators: Azathioprine (2–2.5 mg/kg) or 6‑mercaptopurine (1–1.5 mg/kg) for steroid‑sparing maintenance.
• Biologic agents: Anti‑TNFα (infliximab, adalimumab) or anti‑integrin (vedolizumab) have shown benefit in refractory Quasi‑IBD, though data are limited to case series.
• Probiotics & antibiotics: *VSL#3* or rifaximin (550 mg BID) may help in dysbiosis‑driven cases, but should be used after specialist consultation.

Procedures

• Endoscopic dilation: Rarely needed; reserved for strictures caused by overlapping Crohn’s disease.
• Surgical resection: Considered only when complications such as refractory bleeding or perforation occur; surgery does not cure the disease because inflammation is usually diffuse.

Lifestyle & dietary modifications

• Low‑FODMAP diet: Reduces fermentable carbohydrate load; improves bloating and stool frequency in up to 60 % of patients (Cleveland Clinic, 2021).
• High‑fiber intake (soluble): Oat bran, psyllium can normalize stool form, but avoid insoluble fiber during active flares.
• Hydration: Aim for 2‑3 L/day, especially when experiencing diarrhea.
• Avoid triggers: NSAIDs, excess alcohol, and caffeine if they worsen symptoms.
• Stress management: Mindfulness, CBT, or yoga can lessen symptom perception and improve quality of life.

Living with Quasi‑Inflammatory Bowel Disease

Long‑term management focuses on symptom control, monitoring for complications, and maintaining overall wellness.

Daily management tips

1. Medication adherence: Use pill organizers or smartphone reminders.
2. Track symptoms: Keep a diary of stool frequency, consistency (Bristol stool chart), diet, and stress levels to identify patterns.
3. Regular follow‑up: Schedule gastroenterology visits every 6‑12 months, or sooner if symptoms change.
4. Vaccinations: Stay up‑to‑date, especially for influenza, COVID‑19, and pneumococcal disease; immunosuppressive therapy may affect vaccine response.
5. Bone health: If on chronic steroids, obtain a DEXA scan every 2‑3 years and supplement calcium (1,200 mg) + vitamin D (800‑1,000 IU).
6. Work & school accommodations: Request flexible bathroom access and consider a discreet “medical alert” card.

Psychosocial support

• Join support groups (online forums, local IBD societies).
• Consider counseling for anxiety or depression, which affect up to 30 % of patients.

Prevention

Because the precise cause is unknown, primary prevention is challenging, but risk reduction strategies are useful:

• Quit smoking: Reduces flare frequency by ~40 % (CDC, 2023).
• Limit NSAID use: Prefer acetaminophen for pain; if NSAIDs are necessary, choose the lowest effective dose and consider co‑prescribing a proton‑pump inhibitor.
• Maintain a balanced diet: Emphasize fiber‑rich, low‑sugar foods and adequate omega‑3 fatty acids.
• Probiotic supplementation: Daily *Bifidobacterium* or *Lactobacillus* strains may help maintain a healthier microbiome, especially after antibiotic courses.
• Routine health checks: Early detection of anemia, vitamin B12/folate deficiencies, and bone density loss.

Complications

If left untreated or poorly controlled, Quasi‑IBD can lead to:

• Chronic malnutrition: Protein‑energy deficiency and micronutrient (iron, B12, folate, vitamin D) deficits.
• Osteoporosis/osteopenia: Driven by chronic inflammation and possible steroid exposure.
• Colon cancer risk: Data are limited, but long‑standing inflammation may modestly increase risk; surveillance colonoscopy every 5‑10 years is recommended for patients with ≥8 years of disease.
• Perforation or toxic megacolon: Rare (<1 % of cases) but life‑threatening.
• Psychological impact: Depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

For all other concerns, contact your gastroenterologist or primary‑care provider. Early, personalized care improves outcomes and helps you maintain an active, fulfilling life.

---

Sources: Mayo Clinic (2022), CDC (2023), NIH – National Institute of Diabetes & Digestive and Kidney Diseases, WHO guidelines on IBD, Cleveland Clinic (2021), Gastroenterology Journal reviews 2020‑2024.

```